PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Pentosan Polysulfate: Research & Evidence

Established Evidence

Published research, clinical trial data, and evidence grading for Pentosan Polysulfate across studied indications.

Back to Pentosan Polysulfate overview

Research Summary

Pentosan polysulfate has been FDA-approved for interstitial cystitis since 1996 with 400+ human studies and 20+ IC-specific RCTs. Phase 3 trials (n=149, PMID: 8611679; n=249, PMID: 10806667) established 30-50% patient response rates. Osteoarthritis research is emerging, with pilot studies (n=40, PMC9985017) showing improved pain and cartilage outcomes. A significant safety concern emerged in 2018-2020: pigmentary maculopathy associated with long-term use (>3 years, cumulative doses >500g), prompting an FDA safety communication and recommendation for baseline and periodic eye exams. The MaRVeL osteoarthritis trial is ongoing.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Interstitial cystitis / BPS Tier A 20 FDA-approved 1996; Phase 3 RCTs show 30-50% patient response rate
Osteoarthritis (cartilage protection) Tier C 5 Promising pilot data; MaRVeL trial ongoing for definitive evidence
Venous insufficiency Tier D 2 Limited human data; primarily observational

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (10 sources)

  1. 1. Pentosan polysulfate sodium for interstitial cystitis: a randomized controlled trial Clinical Trial

    Parsons CL, Benson G, Childs SJ, et al. (1996), Journal of Urology

  2. 2. Long-term safety and efficacy of pentosan polysulfate for IC Clinical Trial

    Nickel JC, Barkin J, Forrest J, et al. (2000), Urology

  3. 3. Pentosan polysulfate for knee osteoarthritis: a pilot study Clinical Trial

    Ghosh P, et al. (2023), Osteoarthritis and Cartilage

  4. 4. Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. Study

    Nickel JC, Herschorn S, Whitmore KE, et al. (2015), The Journal of urology

  5. 5. Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials. Study

    van Ophoven A, Vonde K, Koch W, et al. (2019), Current medical research and opinion

  6. 6. Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism. Study

    Sadhukhan PC, Tchetgen MB, Rackley RR, et al. (2002), The Journal of urology

  7. 7. Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis. Study

    Anderson VR, Perry CM (2006), Drugs

  8. 8. The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial. Study

    Tseng CS, Chang SJ, Meng E, et al. (2020), Journal of the Formosan Medical Association = Taiwan yi zhi

  9. 9. Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial. Study

    Siddiq MAB, Liu X, Fedorova T, et al. (2024), BMJ open

  10. 10. Pentosan polysulfate alleviates interstitial cystitis/bladder pain syndrome by modulating bile acid metabolism and activating the TGR5 receptor through gut microbiota regulation. Study

    Zhu Z, Zhu Y, Sun Q, et al. (2025), Bladder (San Francisco, Calif.)